Study of Dasatinib, Androgen Deprivation Therapy and Radiation
Status:
Withdrawn
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Radiation and androgen deprivation is a common modality for patients with localized prostate
cancer. Unfortunately for patients with intermediate to high risk prostate cancer incomplete
tumor eradication and subsequent relapse occurs in 50-75% of patients. The Src pathway
appears to be integral to the pathobiology of prostate cancer and may be fundamental to
radioresistance.